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OBJECTIVE — To explore the relationship between the genetic polymorphisms of PPAR
(Pro12Ala, C1431T, and C-2821T) and the risk of ischemic stroke and to investigate whether
thesegeneticpolymorphismsofPPARwouldmodifytheriskofischemicstrokeamongpatients
with hypertension or diabetes.
RESEARCH DESIGN AND METHODS — The case-control study was conducted with
537 ischemic stroke patients and 537 control subjects. A structured questionnaire was used to
collect information on conventional cardiovascular risk factors and laboratory results. The ge-
netic polymorphisms of PPAR were determined by PCR–restriction fragment–length
polymorphism.
RESULTS — A signiﬁcant interaction was seen between the 2821C allele and diabetes but
notbetweenthisalleleandhypertension.Amarkedlyelevatedriskofischemicstroke(oddsratio
9.7) was found in the subjects with diabetes and the 2821C allele compared with that in those
without these two risk factors.
CONCLUSIONS — The 2821C allele of PPAR was a strong predictor of ischemic stroke
for diabetic patients.
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P
eroxisome proliferator–activated
receptor  (PPAR) is a ligand-
dependent transcription factor in-
volved in the regulation of lipid
metabolism and inﬂammation (1–2). It is
expressed in endothelium, vascular
smooth muscle cells, macrophages, T-
lymphocytes, and human atherosclerotic
lesions(3–7).Indeed,PPARhasbeenre-
ported to play an important role in the
progression of atherosclerosis, which is a
well-known risk factor of stroke (8).
PPAR was proved to prevent post-
ischemic inﬂammation and neuronal
damageinanimalstudies(9).Itmayserve
as potential targets for treating ischemic
stroke. Thus, we aimed to explore the re-
lationship between genetic polymor-
phisms of PPAR and the risk of ischemic
stroke.
RESEARCH DESIGN AND
METHODS— A total of 537 ischemic
stroke patients aged 30–95 years and
conﬁrmedwithcomputedtomographyor
magnetic resonance imaging were re-
cruited from the Department of Neurology
at Chi-Mei Hospital, Lotung Poh-Ai Hos-
pital, Wan-Fang Hospital, and Taipei
Medical University Hospital between
2005 and 2007. A total of 1,636 subjects
aged 30–95 years from the health exam-
inations at Shin-Kong WHS Memorial
Hospital and Wan-Fang Hospital be-
tween 2004 and 2007 were recruited as
candidates for the control group. Among
these candidates, 34 with a stroke history
wereexcluded.Atotalof537controlsub-
jects were then randomly selected from
1,602 candidates and frequency matched
by age (2.5 years) and sex with case
subjects. This case-control study was ap-
proved by the institutional review board
forhumansubjects,andeachsubjectpro-
vided written informed consent prior to
the study. A structured questionnaire was
usedtocollectinformationonconventional
cardiovascular risk factors and laboratory
results. The genetic polymorphisms of
PPAR (C-2821T, Pro12Ala, and C1431T)
were determined by PCR–restriction
fragment–length polymorphism. Details
are described in the online appendix, avail-
able at http://care.diabetesjournals.org/cgi/
content/full/dc09-0717/DC1. Student t
tests,Mann-WhitneyUtests,
2tests,and
logistic regression models were used as
appropriate and performed with the SAS
statistical software (version 9.1). Synergy
index scores were used to evaluate inter-
actionbetweentworiskfactors(10).Pair-
wise linkage disequilibrium between
single nucleotide polymorphism markers
was evaluated by Haploview (11).
RESULTS— The occurrences of hy-
pertension (75.6%), diabetes (45.9%),
and PPAR C-2821C genotype (12.3%)
were more common in case than in con-
trol subjects, but the distribution of
Pro12Ala and C1431T was similar be-
tween the two groups. The percentage of
antihypertension drugs in ischemic
stroke case subjects (66.7%) was similar
to that in control subjects (66.6%). Of
the ischemic stroke case subjects with di-
abetes, 54.1% had pharmacological treat-
ment. The percentage of pharmacological
treatment for diabetes in control subjects
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jects. All genetic polymorphisms were in
Hardy-Weinberg equilibrium. There was
a high degree of linkage disequilibrium
between Pro12Ala and C-2821T.
AfteradjustingforBMI,waistcircum-
ference,ahistoryofeversmoking,dyslip-
idemia, hypertension, diabetes, and
pharmacological treatment for diabetes,
the odds ratio (OR) of PPAR C-2821C
genotype was not signiﬁcant. Compared
with nondiabetic subjects with T-2821T
genotype, an increased risk of ischemic
stroke was observed in TT genotype car-
riers with diabetes (OR 4.2; P  0.07),
and the OR drastically increased to 9.7
(P  0.008) in C allele carriers but not in
C allele carriers without diabetes. Thus,
there was a signiﬁcant joint effect of the
PPAR C-2821T polymorphism and dia-
betes (synergy  index  2.7) on the risk
of ischemic stroke. On the other hand, no
interactionbetweenhypertensionandthe
PPAR C-2821T polymorphism on the
risk of ischemic stroke was found (syn-
ergy  index  0.9).
The risk of ischemic stroke was esti-
mated for each combination of hyperten-
sion, diabetes, and the PPAR 2821C
allele, using nonhypertension, non-
diabetes,andnon-2821Callelecarriersas
the reference group (Table 1). The ORs of
ischemic stroke in hypertension alone or
diabetes alone were 2.7 and 3.5, respec-
tively. Furthermore, the OR increased to
5.3 in the subjects with diabetes and the
PPAR 2821C allele, which was higher
thantheriskinassociationwithhyperten-
sion or diabetes alone. The greatest OR
(11.6) was seen in the subjects with hy-
pertension, diabetes, and the PPAR
2821Callele.Atrendtestindicatedthat
the risk of ischemic stroke increased
along with the accumulating number of
these three risk factors (P  0.0001).
CONCLUSIONS— Our study con-
cluded that there was no relationship be-
tween PPAR Pro12Ala genotype and the
risk of ischemic stroke. The same result
was found by Zafarmand et al. (12), but
the opposite conclusion was made by Lee
et al. (13). The data of genetic polymor-
phism of PPAR C-2821T in diseases
were scarce. This novel genetic variant
was ﬁrst identiﬁed in the Pima Indian
population from Arizona and was re-
portedtoassociatewithmetabolicpredic-
torsoftype2diabetesandobesity(14).In
the present study, we found a joint effect
of the PPAR 2821C allele and diabetes
on the risk of ischemic stroke. Adjusting
for traditional cardiovascular risk factors
and pharmacological treatment for diabe-
tes, the risk of ischemic stroke in the
2821C allele carriers with diabetes was
9.7timesgreaterthanthatofthehomozy-
gous T allele carriers without diabetes.
Higher transcriptional activity was found
in the 2821T allele than in the2821C
allele by using the Dual Luciferase Re-
porter Assay in 3T3-L1 cells (14). This
implied that PPAR could present a pro-
tectiveeffectonischemicstroke.Wuetal.
(9) used a rat model to prove PPAR to
be a critical factor for protection against
neuronal apoptosis and cerebral infarc-
tion by the mediated 14-3–3ε protein. In
addition, PPAR was reported to be an
important regulator of endothelial func-
tion in the cerebral circulation, especially
under conditions of high fat–induced
stress (15).
In the present study, we found that
the risk of ischemic stroke in subjects
with hypertension, diabetes, and the
2821C allele was 2.6 times higher than
thatinthesubjectswithhypertensionand
diabetes. Therefore, the combination of
hypertension, diabetes, and the PPAR
2821C allele was a strong predictor of
ischemic stroke. Further studies in other
populations will be very useful in estab-
lishing the contribution of this C-2821T
polymorphism to ischemic stroke.
In conclusion, there was a strong
interaction between the PPAR 2821C
allele and diabetes with regard to risk
of ischemic stroke. Thus, the PPAR
2821C allele was a strong predictor of
ischemic stroke for diabetic patients, and
PPAR may serve as a potential target for
treating ischemic stroke.
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